Insights to Impact:
A Selection of Our Recent Work

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to the recent approval of a competing cancer therapy in earlier lines of treatment

A real-world data (RWD) provider wanted to identify key use cases, unmet needs, and future opportunities in the RWD market, with a particular focus on clinical, genomic, and pathology RWD and biopharma users

A large life science tools provider was interested in characterizing the genome engineering and engineered cell line market to identify potential opportunities to participate in the space

A diagnostics company asked DeciBio to convene an advisory board (ad board) to help it position its relatively new somatic oncology genomic profiling product in an already competitive market

A cell therapy developer preparing for a NASDAQ listing needed financial projections, a valuation, and support on investor messaging

A global healthcare investment firm wanted to perform a commercial due diligence (CDD) prior to investment in a company producing a novel handheld diagnostic